Free tool
FAERS Monitor: Zerbaxa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206829 or its brand name (Zerbaxa, Ceftolozane Sulfate, Tazobactam Sodium). Reports on generic versions are filed under their own applications.
Reports
982
Serious
670
68% of reports
Hospitalization
274
Death reported
233
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use139
- product use in unapproved indication128
- no adverse event90
- death81
- product use issue67
- pathogen resistance54
- drug ineffective44
- acute kidney injury36
- drug resistance30
- encephalopathy27
- incorrect dose administered26
- pancytopenia26
- pneumonia26
- renal failure25
- septic shock25
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 45 |
| 2016 | 85 |
| 2017 | 126 |
| 2018 | 135 |
| 2019 | 126 |
| 2020 | 145 |
| 2021 | 42 |
| 2022 | 55 |
| 2023 | 82 |
| 2024 | 67 |
| 2025 | 49 |
| 2026 | 25 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,177 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pathogen resistanceSignal | 54 | 127.6 | 98.4 | 6,622 |
| drug resistanceSignal | 30 | 25.0 | 17.6 | 669 |
| encephalopathySignal | 27 | 23.6 | 16.2 | 561 |
| septic shockSignal | 25 | 12.3 | 8.4 | 249 |
| product use in unapproved indicationSignal | 128 | 11.1 | 9.4 | 1,175 |
| no adverse eventSignal | 90 | 10.6 | 8.7 | 783 |
| pancytopeniaSignal | 26 | 10.0 | 6.8 | 201 |
| product use issueSignal | 67 | 7.6 | 6.1 | 383 |
| acute kidney injurySignal | 36 | 5.0 | 3.7 | 113 |
| renal failureSignal | 25 | 4.0 | 2.7 | 54 |
| off label useSignal | 139 | 3.4 | 2.9 | 243 |
| incorrect dose administeredSignal | 26 | 2.4 | 1.7 | 21 |
| deathSignal | 81 | 2.0 | 1.6 | 42 |
| pneumonia | 26 | 1.7 | 1.2 | 7 |
| drug ineffective | 44 | 0.7 | 0.5 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.